Unmet Need in Essential Thrombocythemia and Polycythemia Vera

被引：3
|
作者：
Kishtagari, Ashwin [1 ]
Gerds, Aaron T. [1 ]
机构：
[1] Cleveland Clin, Leukemia & Myeloid Disorders Program, Taussig Canc Inst, 9500 Euclid Ave,CA60, Cleveland, OH 44120 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2021年 / 35卷 / 02期
关键词：
Myeloproliferative neoplasms; MPN; ET; PV; Bomedemstat; IFN-alpha; Idasanutlin; Givinostat;
D O I：
10.1016/j.hoc.2021.01.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Consensus guidelines have helped to standardize the care of patients with essential thrombocythemia and polycythemia vera, focusing on reducing the risk of thrombosis, mitigating symptoms, and avoiding therapies that may accelerate disease progression. However, many unmet needs still exist ranging from the roll of antiplatelet therapy in ET to medications that reduce disease progression. Retrospective studies suggest an improvement in myelofibrosis-free survival for treatment with interferons; new agents are looking to also enact disease modification. © 2021 Elsevier Inc.
引用
收藏
页码：295 / 303
页数：9
相关论文
共 50 条
  • [31] Telomerase and telomeres in polycythemia vera and essential thrombocythemia.
    Gallamini, A
    Ferraris, AM
    Mattei, D
    Pujic, N
    Mangerini, R
    Rapezzi, D
    Tavera, S
    Gaetani, GF
    BLOOD, 2005, 106 (11) : 317B - 317B
  • [32] Part 2: Essential thrombocythemia and polycythemia vera - Preface
    Mammen, EF
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (04): : 305 - 306
  • [33] Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia
    Dingli D.
    Tefferi A.
    Current Hematologic Malignancy Reports, 2006, 1 (2) : 69 - 74
  • [34] Management of symptoms in polycythemia vera and essential thrombocythemia patients
    Radia, Deepti
    Geyer, Holly L.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 340 - 348
  • [35] Is myocardial infarction as frequent in essential thrombocythemia as in polycythemia vera?
    Randi, ML
    Rossi, C
    Zerbinati, P
    Girolami, A
    THROMBOSIS AND HAEMOSTASIS, 1997, : PS182 - PS182
  • [36] Evidence and expertise in the management of polycythemia vera and essential thrombocythemia
    Finazzi, G.
    Barbui, T.
    LEUKEMIA, 2008, 22 (08) : 1494 - 1502
  • [37] Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
    Silver, Richard T.
    Kiladjian, Jean-Jacques
    Hasselbalch, Hans Carl
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (01) : 49 - 58
  • [38] Evidence and expertise in the management of polycythemia vera and essential thrombocythemia
    G Finazzi
    T Barbui
    Leukemia, 2008, 22 : 1494 - 1502
  • [39] Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera
    H Reikvam
    R V Tiu
    Leukemia, 2012, 26 : 563 - 571
  • [40] Current management strategies for polycythemia vera and essential thrombocythemia
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    BLOOD REVIEWS, 2020, 42
12345